| Name | Nafamostat mesylate |
| Description | Nafamostat mesylate (FUT-175), a synthetic serine protease inhibitor, has been used for the treatment of allergic disorders such as asthma, allergic rhinitis and atopic dermatitis. |
| In vitro | Nafamostat Mesylate inhibits both the activation of NF-κB and apoptosis induced by gemcitabine and restrains the growth of pancreatic tumors. At a dosage of 10 mg/kg, it exhibits an inhibitory effect on wounds induced by trypsin. Furthermore, at the same dosage, Nafamostat Mesylate suppresses tryptase activity in mouse skin. |
| In vivo | Nafamostat mesilate significantly inhibits the release of platelet β-thromboglobulin (βTG) and the release of elastase from neutrophils. It also prevents the formation of complexes between the C1 inhibitor and both prekallikrein and FXIIa. Furthermore, Nafamostat mesilate inhibits the extrinsic pathway activity mediated by the TF-F.VIIa complex, leading to the production of F.Xa, with an IC50 value of 0.1 μM. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility Information | DMSO : 45 mg/mL (83.4 mM)
H2O : 54 mg/mL (100 mM)
|
| Keywords | Threonine proteases | FUT175 | Apoptosis | Serine endopeptidases | SARS-CoV | Ser/Thr Protease | SARS coronavirus | Serine proteases | Nafamostat mesylate | Nafamostat Mesylate | Inhibitor | inhibit | FUT 175 | Nafamostat |
| Inhibitors Related | Stavudine | Hydroxychloroquine | Tributyrin |
| Related Compound Libraries | Kinase Inhibitor Library | Anti-Cancer Clinical Compound Library | Drug Repurposing Compound Library | Anti-Viral Compound Library | Anti-Aging Compound Library | Bioactive Compounds Library Max | Anti-Cancer Drug Library |
United States
